Play all audios:
PADA-1 is the first trial to demonstrate benefit from a treatment-switching strategy guided by active monitoring of _ESR1_ mutations in plasma circulating tumour DNA (ctDNA) from patients
with breast cancer. The results of this trial raise important questions about the specific treatment approach tested, and the feasibility of trials incorporating longitudinal ctDNA analyses
to anticipate resistance and guide treatment. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access
through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to
this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy
now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer
support REFERENCES * Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M. & Schiff, R. ESR1 mutations — a mechanism for acquired endocrine resistance in breast cancer. _Nat. Rev.
Clin. Oncol._ 12, 573–583 (2015). Article CAS Google Scholar * Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. _Nat. Genet._ 45, 1439–1445 (2013).
Article CAS Google Scholar * Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. _Nature_ 490, 61–70 (2012). Article Google Scholar * Fribbens, C. et
al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. _J. Clin. Oncol._ 34, 2961–2968 (2016). Article CAS Google Scholar * Chandarlapaty, S.
et al. Prevalence of _ESR1_ mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. _JAMA Oncol._ 2, 1310–1315 (2016).
Article Google Scholar * Turner, N. C. et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: a combined analysis
of the phase III SoFEA and EFECT trials. _Clin. Cancer Res._ 26, 5172–5177 (2020). Article CAS Google Scholar * Bidard, F.-C. et al. Elacestrant (oral selective estrogen receptor
degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III
EMERALD trial. _J. Clin. Oncol._ 40, 3246–3256 (2022). Article CAS Google Scholar * Bidard, F.-C. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer
with rising _ESR1_ mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. _Lancet Oncol._ 23, 1367–1377 (2022). Article
CAS Google Scholar * Toy, W. et al. Activating _ESR1_ mutations differentially affect the efficacy of ER antagonists. _Cancer Discov._ 7, 277–287 (2017). Article CAS Google Scholar *
O’Leary, B. et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. _Cancer Discov._ 8, 1390–1403 (2018). Article
Google Scholar Download references ACKNOWLEDGEMENTS B.O’L. acknowledges institutional funding from the UK National Institute for Health Research to the Royal Marsden and the Institute of
Cancer Research Biomedical Research Centre. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Breast Cancer Research and Radiotherapy & Imaging, The Institute of Cancer Research, London, UK
Ben O’Leary * The Royal Marsden Hospital, London, UK Ben O’Leary Authors * Ben O’Leary View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING
AUTHOR Correspondence to Ben O’Leary. ETHICS DECLARATIONS COMPETING INTERESTS B.O’L. has received institutional research funding through the Institute of Cancer Research from Pfizer and has
been a consultant to Merck Serono. ADDITIONAL INFORMATION RELATED LINKS CLINICALTRIALS.GOV: https://clinicaltrials.gov/ct2/show/NCT03079011 RIGHTS AND PERMISSIONS Reprints and permissions
ABOUT THIS ARTICLE CITE THIS ARTICLE O’Leary, B. PADA-1 trial: _ESR1_ mutations in plasma ctDNA guide treatment switching. _Nat Rev Clin Oncol_ 20, 67–68 (2023).
https://doi.org/10.1038/s41571-022-00712-3 Download citation * Published: 23 November 2022 * Issue Date: February 2023 * DOI: https://doi.org/10.1038/s41571-022-00712-3 SHARE THIS ARTICLE
Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided
by the Springer Nature SharedIt content-sharing initiative